S
ROIV icon

SignatureFD’s Roivant Sciences ROIV Stock Holding History

SignatureFD’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Buy
4,047
+1,217
+43% +$36K ﹤0.01% 1260
2026
Q1 		$78.4K Buy
2,830
+448
+19% +$11.5K ﹤0.01% 1473
2025
Q4 		$51.7K Buy
2,382
+315
+15% +$6.21K ﹤0.01% 1633
2025
Q3 		$31.3K Buy
2,067
+165
+9% +$2.04K ﹤0.01% 1891
2025
Q2 		$21.4K Buy
1,902
+763
+67% +$8.27K ﹤0.01% 2016
2025
Q1 		$11.5K Buy
1,139
+606
+114% +$6.55K ﹤0.01% 2302
2024
Q4 		$6.3K Buy
533
+107
+25% +$1.26K ﹤0.01% 2519
2024
Q3 		$4.92K Buy
426
+104
+32% +$1.18K ﹤0.01% 2575
2024
Q2 		$3.4K Sell
322
-3
-0.9% -$33 ﹤0.01% 2622
2024
Q1 		$3.43K Buy
325
+38
+13% +$410 ﹤0.01% 2656
2023
Q4 		$3.22K Buy
287
+133
+86% +$1.3K ﹤0.01% 2638
2023
Q3 		$1.8K Buy
154
+66
+75% +$746 ﹤0.01% 2799
2023
Q2 		$887 Sell
88
-251
-74% -$2.25K ﹤0.01% 2995
2023
Q1 		$2.5K Sell
339
-379
-53% -$3.12K ﹤0.01% 2735
2022
Q4 		$5.74K Buy
718
+671
+1,428% +$3.73K ﹤0.01% 2410
2022
Q3 		$0 Buy
+47
New +$182 ﹤0.01% 3309

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

SignatureFD's ROIV Position: Q2 2026 in Review

SignatureFD increased its Roivant Sciences (ROIV) stake by 43% in Q2 2026, buying an estimated $36K and bringing the position to 4,047 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

SignatureFD first reported a position in ROIV in Q3 2022 and has held it in 16 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • SignatureFD held 4,047 shares of Roivant Sciences worth $143K as of Q2 2026.
  • SignatureFD bought 1,217 Roivant Sciences shares in Q2 2026, an estimated $36K.
  • Roivant Sciences made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1260 holding.
  • SignatureFD first reported a position in Roivant Sciences in Q3 2022 and has held it in 16 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.